This is a correction to: Lori J Wirth, Bruce Robinson, Valentina Boni, Daniel S W Tan, Caroline McCoach, Erminia Massarelli, Lisa M Hess, Min-Hua Jen, Jennifer Kherani, Elizabeth Olek, Vivek Subbiah, Patient-Reported Outcomes with Selpercatinib Treatment Among Patients with RET-Mutant Medullary Thyroid Cancer in the Phase I/II LIBRETTO-001 Trial, The Oncologist, Volume 27, Issue 1, January 2022, Pages 13–21, https://doi.org/10.1002/onco.13977
In the originally published version of this manuscript, the heading at the top of the supplementary materials contained the wrong author name (Jan Schellens et al.). This has now been updated to Lori J. Wirth et al.
In addition, the following data (marked in bold in this correction notice) on page 20 and 21 of supplementary materials was erroneously transposed:
| CFB statusb | |||
| Worsened, % | 17.9 | 8.3 | 26.3 |
| Stable, % | 37.5 | 37.5 | 42.1 |
| Improved, % | 44.6 | 54.2 | 31.6 |
This error has been corrected as follows:
| CFB statusb | |||
| Worsened, % | 17.9 | 26.3 | 8.3 |
| Stable, % | 37.5 | 42.1 | 37.5 |
| Improved, % | 44.6 | 31.6 | 54.2 |